Oruka Therapeutics (NASDAQ:ORKA) Earns “Buy” Rating from BTIG Research

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “buy” rating reissued by equities researchers at BTIG Research in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $73.00 target price on the stock. BTIG Research’s price target would suggest a potential upside of 84.09% from the stock’s current price.

Other research analysts have also issued research reports about the stock. Piper Sandler initiated coverage on shares of Oruka Therapeutics in a report on Thursday, December 18th. They set an “overweight” rating and a $75.00 price target for the company. Stifel Nicolaus upped their price objective on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a research note on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Thursday, January 22nd. Jefferies Financial Group assumed coverage on shares of Oruka Therapeutics in a report on Thursday, November 13th. They issued a “buy” rating and a $45.00 target price on the stock. Finally, UBS Group began coverage on shares of Oruka Therapeutics in a research report on Wednesday, January 7th. They set a “buy” rating and a $50.00 price target on the stock. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $56.44.

Oruka Therapeutics Stock Up 24.0%

Shares of NASDAQ ORKA traded up $7.67 during trading on Friday, reaching $39.66. The company had a trading volume of 398,567 shares, compared to its average volume of 420,671. The company’s fifty day moving average price is $32.68 and its 200-day moving average price is $27.32. Oruka Therapeutics has a 12 month low of $5.49 and a 12 month high of $39.66. The stock has a market cap of $1.92 billion, a P/E ratio of -20.45 and a beta of -0.38.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings data on Thursday, March 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.16. As a group, equities analysts predict that Oruka Therapeutics will post -3.41 earnings per share for the current year.

Insider Activity

In other news, insider Joana Goncalves sold 7,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $32.37, for a total transaction of $226,590.00. Following the completion of the sale, the insider owned 34,018 shares of the company’s stock, valued at $1,101,162.66. This trade represents a 17.07% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. In the last quarter, insiders sold 21,000 shares of company stock worth $663,530. 24.69% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada grew its holdings in Oruka Therapeutics by 47.2% in the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after purchasing an additional 365 shares during the period. Kennedy Capital Management LLC raised its holdings in shares of Oruka Therapeutics by 0.9% during the fourth quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock valued at $1,476,000 after purchasing an additional 420 shares during the period. Russell Investments Group Ltd. boosted its position in shares of Oruka Therapeutics by 35.0% during the 4th quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company’s stock worth $92,000 after purchasing an additional 788 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Oruka Therapeutics by 62.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,352 shares of the company’s stock valued at $71,000 after buying an additional 904 shares during the period. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of Oruka Therapeutics in the 4th quarter valued at about $37,000. 56.44% of the stock is owned by institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.